Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3kuZ6vx
via IFTTT